INTRODUCTION
Tenofovir Disoproxil Fumarate (TDF) is one of the newest and more
tolerable backbone of highly active antiretroviral therapy (HAART) in
the class of nucleotide reverse transcriptase inhibitor (NRTI). In 2016,
World Health Organization (WHO) published a consolidated guideline that
recommended Tenofovir based regimen as the first line for adults and
adolescents and henceforward this regimen has been extensively rolled
out11ReferencesWHO (2018, January 1). Updated recommendations on the first line and
second line antiretroviral regimens and post exposure prophylaxis and
recommendations on early infant diagnosis of HIV. Despite its
excellent safety profile and tolerability TDF is known to cause proximal
tubule renal dysfunction. TDF renal tubulopathy can manifest as Fanconi
syndrome (FS), Acute kidney injury or chronic kidney disease22Verhelst
D, Monge M, MeynardJL, et al. Fanconi syndrome and renal failure
induced by tenofovir: a first case report, Am J Kidney
Dis , 2002, vol. 40(pg. 13313). Here, we present the case of a middle
age African female on Tenofovir based regimen who developed Fanconi
syndrome after 12 years of Tenofovir based HAART.